attach research report excerpt
research report written
entir broker partner auerbach
grayson auerbach grayson
auerbach grayson distributing/provid
research report consider
report revenu growth normalis non-gaap ep
growth beat theme us mask sale growth
sustain market share gain flow gener categori world-wide
saa revenu growth exclud oper cash flow
versu pcp exclud one-off litig settlement time tax payment
 expens guidanc maintain
ep upgrad approxim reflect improv earn leverag oper
cash flow flow lower interest also note modest tax tailwind
balanc
takeaway earn call new insight autom mask
resuppli solut term compet prepared next round
us fund chang medicar competit bid long sale runway ahead
saa long-term post-acut healthcar custom under- penetr face
fund pressur consolid risk progress integr end end
manag copd patient medic devic softwar aspect
strategi support market share gain resm respir devic
ventil portabl oxygen concentr thought airsens
platform innov
dcf price target per cdi impli cash ep
ev/ebitda trade valuat premium intern med-tech
peer see justifi uniqu synergi compani medic
devic saa busi
risk advers reimburs cut sleep apnoea fund product
launch competitor fx volatil fph earn
announc singl payment amount competit bid
 resumpt share buy-back program
overweight saa gain drive
maintain overweight rate lift price target
resm result beat ep forecast
gain popular invok structur chang channel
appear favour look ahead chang
also make broader medic devic busi resili face
next round competit bid reimburs chang next year
remain top pick medic devic coverag
snapshot report revenu growth normalis
non-gaap ep growth beat theme us
mask sale growth sustain market share gain flow gener
categori world-wide saa revenu growth exclud
oper cash flow versu pcp exclud one-off litig
settlement time tax payment expens guidanc maintain
model chang ep upgrad approxim reflect improv
earn leverag oper cash flow flow lower interest also
note modest tax tailwind balanc
takeaway earn call new insight autom mask
resuppli solut term compet prepared next
round us fund chang medicar competit bid long sale
runway ahead saa long-term post-acut healthcar custom under-
penetr face fund pressur consolid risk progress
integr end end manag copd patient medic
devic softwar aspect strategi support market share gain
ventil portabl oxygen
concentr thought airsens platform innov
valuat dcf price target per cdi impli cash ep
ev/ebitda trade valuat premium
intern med-tech peer see justifi uniqu synergi
compani medic devic saa busi
risk catalyst
risk advers reimburs cut sleep apnoea fund product
launch competitor fx volatil fph earn
earn announc singl payment amount
launch accret resumpt share buy-back program
share issu cdi
analyst share compani n/a
issu wilson advisori stockbrok limit wilson abn australian financi servic licenc particip asx group
read conjunct disclosur disclaim report import disclosur regard compani subject report
explan recommend found end document
health equip suppli
profit loss
fund equiti
fund debt
fund cash
health equip suppli
unpack us mask result suggest durabl benefici chang channel
structur mask sale america grew strip small contribut
propel period saw appar impact competit us mask launch
fph respiron sever factor play includ direct product-level
advantag launch new sub-categori increas adher driven
technolog solut broader custom particip autom mask re-suppli
program key structur solut appear insul mask
busi brand switch increasingli marketplac prescrib mask
brand-neutr way hme distributor level may less justif medic
econom offer brand-switch opportun point re-suppli
resm best-plac manufactur head competit bid
outcom announc around august/septemb market
expect modest reset averag sell price particularli mask ventil
categori resuppli solut engend sticki off-set asp declin
market share increas utilis assess us mask utilis /patient/year
slowli rise lead posit flow gener market well
posit contract larg hme custom portfolio basi volume-pric trade-off
high singl digit growth outlook saa probabl realist long-dat initi
thought characteris manag conserv assess skill
nurs snf homecare/hospic sector under-penetr enterpris
softwar perspect offer tam least signific hme marketplac
brightre success snf face new challeng reimburs regim
switch patient driven payment model increas demand softwar
level
reimburs patient move differ care set medium term
drive uptak softwar solut market matrix feedback
suggest new adopt slow initi bear mind fund
chang implement octob snf januari longer
term snf provid market consolid drive higher demand
streamlin patient admiss access
correct
propeller-oxygen-niv continuum copd treatment medic devic overlay
snf/h set describ progress propel includ sever pilot
piec pharma respiratori medicin deliveri still much work done
codifi streamlin reimburs access patient progress toward
sever diseas clear end end approach take deliv larg
competit advantag copd therapi decisions/transit integr out-
of-hospit softwar ecosystem success strategi could make difficult
altern therapi eg fph nasal highflow break copd homecar
respiratori connect offer potenti platform upsid view
new flow gener platform airsens could provid tactic prior
next round competit bid term innov medic devic connect
like theme import new opportun identifi sit
support mode therapi integr longitudin natur histori
copd could import term higher patient captur retent rate
improv reimburs snf/h oper lower cost deliv
health equip suppli
tabl resm result vs wilson forecast pcp
earn upgrad leverag earn chang ebitda line rel modest
due improv leverag forecast period sale mix favour mask higher-
end devic modest cost assumpt saa improv oper cash
flow reduc net interest estim assess potenti re-initi buy-back
scheme
ab varamerica flow mask flow mask net gross amortis tax rate equiti method net non-gaap revenu sale revenu ebitda normalis npat normalis normalis ep normalis
health equip suppli
resm inc develop manufactur sell medic devic treatment sleep disord breath respiratori
diseas recent year compani built acquir way lead posit enterpris softwar system appeal out-of-
hospit healthcar provid includ skill nurs homecar hospic
maintain overweight rate lift price target result beat ep forecast
us mask busi achiev sale growth notwithstand new competitor launch autom resuppli solut
gain popular invok structur chang channel appear favour look ahead chang also
make broader medic devic busi resili face next round competit bid reimburs chang next year
remain top pick medic devic coverag
grow easier access diagnosi sleep disord
rel short product cycl refresh price point
new devic area
gross margin expos fx aud sgd vs usd
 sg typic net sale
product mix higher-end apap ventil bilevel mask
higher gross margin
competit intensifi low-end cpap market
restor sustain industri us devic volum flow
increment margin benefit mix shift apap
risk view
increas competit price point
slower-than-expect market growth particularli challeng
price reimburs challeng usa elsewher
relat poor complianc cpap
net debt averag next month impli net
leverag
health equip suppli
disclaim disclosur
